Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T20:52:29.655Z.
Calculation as of: 2026-10-06T20:52:29.655Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 05f4ae4a030aaca39f2691a5695262832c6d48704f11c5316ed8238ac0b3761e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Niki BioSolutions, Inc.
Market Cap
$403887.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$378849.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$481786.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$667469.00
Price/OCF Ratio
N/A
TTM Avg
758247.42
3Y Avg
2252375.22
5Y Avg
2252375.22
Market Cap
$110112.00
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niki BioSolutions, Inc. (NIKI) | $403887.00 | N/A | N/A | N/A | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | N/A | N/A | N/A | N/A |
| XORTX Therapeutics Inc. (XRTX)vs › | $481786.00 | N/A | N/A | N/A | N/A |
| VivoSim Labs, Inc. (VIVS)vs › | $518606.00 | N/A | N/A | N/A | N/A |
| HCW Biologics Inc. (HCWB)vs › | $545796.00 | N/A | N/A | N/A | N/A |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | N/A | N/A | N/A | N/A |
| China SXT Pharmaceuticals, Inc. (SXTC)vs › | $667469.00 | N/A | 758247.42 | 2252375.22 | 2252375.22 |
| Silexion Therapeutics Ltd. (SLXN)vs › | $110112.00 | N/A | N/A | N/A | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $716854.00 | 0.01 | 0.16 | 40.30 | 40.30 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
